Prahs
Acquired2 known investors
PRA Health Sciences (prahs.com) is a contract research organization for clinical drug development, acquired by ICON plc in 2021.
Also known as PRA Health Sciences · PRA International
Investors · 2
Company profile
researched Aug 2026PRA Health Sciences, operating at prahs.com, is a contract research organization (CRO) headquartered in Raleigh, North Carolina, that provides clinical development services to pharmaceutical and biotechnology sponsors. Its service portfolio spans clinical trial management, statistical analysis, data management, medical writing, and regulatory and drug development consulting, covering all phases of clinical development. The company has described itself as a top-five CRO that has worked on more than 100 marketed drugs across multiple therapeutic areas.
The company also operates bioanalytical laboratory capabilities through two facilities, one in Lenexa, Kansas (North America) and one in Assen, the Netherlands (Europe). These laboratories provide small and large molecule analysis for pre-clinical and Phase I-IV trials, flow cytometry, analysis of radioisotope compounds and biohazardous samples, immunogenicity testing, biomarker work, and FACS analysis. PRA has also run a COVID-19 monitoring program and published bioanalytical method work, including LC-MS/MS and LC-HR-MS/MS quantitation methods.
In 2021 PRA Health Sciences was acquired by ICON plc and became a wholly owned unit of ICON; the combined organization operates under the ICON name.
Founding story
The company began in 1976 as the Anti-Inflammatory Drug Study Group, a research organization focused on inflammation, and was renamed PRA in 1982 as its therapeutic scope broadened.
Business model
PRA Health Sciences provides outsourced clinical research and drug development services on a contract basis to pharmaceutical and biotechnology sponsors, spanning clinical trial management, data management, statistical analysis, medical writing, regulatory and drug development consulting, and bioanalytical laboratory testing across all clinical phases.
Traction
The company reported 14,000+ employees covering 85+ countries and work on more than 100 marketed drugs. Following the merger, the combined ICON entity reported approximately 38,000 employees as of 1 July 2021.
Latest developments
In June 2021 PRA Health Sciences partnered with Veradigm to build an electronic health record-based clinical research network in the United States intended to reach around 25,000 physicians and 40 million patients. The ICON acquisition closed in 2021. Subsequent activity under the ICON name includes a partnership with Advarra to launch a network of connected clinical trial sites integrating ICON's trial solutions with Advarra's site CTMS, eISF and eSource systems (March 2026), a new research facility in San Antonio, Texas with satellite clinics in Houston and Lawrence, Kansas (May 2026), a partnership with Banyan BioInnovations (May 2026), and selection of Microsoft to support AI-enabled clinical development (June 2026).
▸Full profile — market position, technology, go-to-market, geography, history
Market position
PRA Health Sciences has positioned itself as a top-five clinical research organization, with reported experience on more than 100 marketed drugs. Comparable organizations in the CRO and clinical research services sector include IQVIA, Syneos Health, Medpace, WuXi AppTec, Charles River Laboratories and Labcorp Drug Development. Following the ICON transaction, the combined entity is presented as a large-scale clinical research and healthcare intelligence provider.
Technology
The company operates two bioanalytical laboratories (Lenexa, Kansas and Assen, the Netherlands) offering small and large molecule analysis, mass spectrometry-based quantitation (including LC-MS/MS and LC-HR-MS/MS methods), flow cytometry and FACS analysis, immunogenicity testing, biomarker analysis, and handling of radioisotope compounds and biohazardous samples. Post-acquisition, the ICON organization has pursued electronic health record-based research networks and AI-enabled clinical development capabilities.
Go-to-market
Pharmaceutical and biotechnology companies developing drugs and requiring outsourced clinical development, data and bioanalytical services across Phase I-IV and post-approval studies.
Geography
Headquartered in Raleigh, North Carolina (4139 Parklake Avenue, Suite 400, Raleigh, NC 27612), with reported coverage of 85+ countries and bioanalytical laboratories in Lenexa, Kansas and Assen, the Netherlands. After the merger, the combined ICON organization spans 150 locations in 47 countries.
History
The organization was founded in 1976 as the Anti-Inflammatory Drug Study Group and was renamed PRA in 1982 as it expanded beyond inflammation into other therapeutic areas. It later traded publicly under the ticker PRAH. In February 2021 PRA Health Sciences signed a merger agreement with ICON plc, under which ICON paid $80 in cash per share plus 0.4125 ICON shares to PRA shareholders; the roughly $12bn transaction closed in 2021, making PRA a wholly owned unit of ICON. The merged company operates under the ICON name with approximately 38,000 employees across 150 locations in 47 countries as of 1 July 2021.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsPRA Health Sciences partnered with Veradigm to establish an electronic health record-based clinical research network in the US, intended to reach around 25,000 physicians and 40 million patients.
The companies signed a merger agreement under which ICON would pay $80 in cash per share and 0.4125 shares of its stock to PRA shareholders.
ICON completed its acquisition of PRA Health Sciences for total consideration of approximately $12bn, paying $80 in cash per share plus 0.4125 ICON shares. PRA became a wholly owned unit of ICON, and the merged company operates under the ICON name with about 38,000 employees across 150 locations in 47 countries as of 1 July 2021.
$12B source ↗
PRA Health Sciences announced the opening of a new bioanalytical laboratory in Assen, the Netherlands, complementing its Lenexa, Kansas facility.
PRA Health Sciences launched a COVID-19 monitoring program.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- PRA Health Sciences | GHDxghdx.healthdata.org · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Prahs do?
- PRA Health Sciences (prahs.com) is a contract research organization for clinical drug development, acquired by ICON plc in 2021.
- Who are Prahs's investors?
- Prahs's investors include Genstar, The Argentum Group.